-
From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers
Monday, April 4, 2022 - 8:51pm | 481Read More...With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ: MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and...
-
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
Friday, December 10, 2021 - 5:21pm | 900Read More...This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning more about the changes that have taken place since, Benzinga spoke with Robert Barrow, the firm’s chief development...
-
EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation
Tuesday, August 31, 2021 - 11:01am | 1218Read More...A lot has changed since Benzinga last spoke with Kevin O’Leary, businessman, author, "Shark Tank's" Mr. Wonderful. Most notably, his deal flow is more so concentrated around emerging markets such as DeFi — a finance model that replicates market-making, borrowing, lending...
-
Fintech Focus Roundup For June 13, 2021
Saturday, June 12, 2021 - 12:08pm | 1404Read More...Atom Finance Launches White-Labeled Data Experiences, Partners With Inter Atom Finance, a modern financial knowledge platform, announced its first product integration partnership with Inter, a digital platform for banking, shopping, insurance, and investments. Public Launches Brand Campaign...
-
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' Psychedelics
Thursday, May 13, 2021 - 2:46pm | 389Read More...Mind Medicine Inc (NASDAQ: MNMD) was started to address mental wellness, CEO and co-founder J.R. Rahn told Benzinga's Global Small Cap Conference Thursday. MindMed is discovering and developing new and existing psychedelic molecules as medicines through the FDA pathway,...
-
Fintech Focus Roundup For May 2, 2021
Sunday, May 2, 2021 - 8:17am | 975Read More...Apex Fintech Solutions Announces Blow-Out Earnings Ahead Of NYSE Listing What Happened: Blank-check company Northern Star Investment Corporation II announced that Apex Fintech Solutions LLC, a business-to-business platform that powers innovation in fintech, investing and wealth management,...
-
Exclusive: MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine
Friday, April 30, 2021 - 9:05am | 1137Read More...Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a leading medicine biotech company in psychedelics, this week began trading on the Nasdaq exchange. In light of the momentous occasion, Benzinga spoke with MindMed co-founder and CEO J.R. Rahn, as well as board member Kevin O’Leary...
-
Fintech Focus Roundup For February 20, 2020
Saturday, February 20, 2021 - 8:21am | 1565Read More...Fintech Spotlight: How Morpher Lets You Buy Apple, On A Weekend, With As Little As $1 When typically discussed, blockchain lacks a utility component. That’s what Morpher CEO Martin Fröhler is looking to change. Fröhler is a mathematician, with a background in quantitative finance,...
-
Is MindMed Creating The Tesla Of Mental Health? Thoughts From CEO JR Rahn, Investor Kevin O'Leary
Thursday, December 10, 2020 - 10:38am | 516Read More...Mind Medicine (OTC: MMEDF) Co-Founder and CEO J.R. Rahn and investor Kevin O’Leary spoke this week at the inaugural Benzinga Global Small Cap Conference. O’Leary on MindMed: O’Leary for long had avoided the cannabis sector, despite getting numerous deals offered to him....
-
Fintech Focus Roundup For November 28, 2020
Friday, November 27, 2020 - 7:21pm | 1747Read More...Metromile To Go Public Via SPAC, Expand Licensing What Happened: In partnership with INSU Acquisition Corp. II, a SPAC sponsored by the insurance-focused Cohen & Company Inc., insurtech Metromile announced it will become a publicly listed company that would trade on the Nasdaq exchange under...
